Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Ustekinumab products may decrease the protective ... Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows ... consolidation and critical generic medicines product withdrawal is adding to the uncertainty.

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd ... (dextromethorphan HBr – bupropion HCl) product. Auvelity is approved in the U.S. for major depressive ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.